Page last updated: 2024-12-10

c 31g

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

C 31G: mixture of above cpds [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3086239
SCHEMBL ID15532154
MeSH IDM0115548

Synonyms (5)

Synonym
c-31g
86903-77-7
c 31g
SCHEMBL15532154
carboxymethyl-dodecyl-dimethylazanium;n,n-dimethyldodecan-1-amine oxide

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" C31G was shown to be safe to both vaginal and rectal mucosal tissues and to the microflora with repeated daily use."( Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque.
Balkus, JE; Hillier, SL; Patton, DL; Sweeney, YT, 2006
)
0.33
" Measured outcomes included pregnancy rates, continuation rates, adverse events, and acceptability."( Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial.
Archer, D; Barnhart, K; Blithe, D; Burke, AE; Carr, BR; Creinin, MD; Jensen, JT; Liu, J; Schlaff, W; Thomas, M; Walsh, TL; Wan, LS; Westhoff, C; Wu, H, 2010
)
0.36
" Two serious adverse events were deemed possibly related to study product and neither occurred in the C31G group."( Contraceptive efficacy, acceptability, and safety of C31G and nonoxynol-9 spermicidal gels: a randomized controlled trial.
Archer, D; Barnhart, K; Blithe, D; Burke, AE; Carr, BR; Creinin, MD; Jensen, JT; Liu, J; Schlaff, W; Thomas, M; Walsh, TL; Wan, LS; Westhoff, C; Wu, H, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Kinetic studies of absorption and disposition after oral dosing in mice with [3H]C31G were used to determine the body burden (0."( Mice and rabbit models for oral and percutaneous absorption and disposition of amphoteric surfactant C31G.
Hahn, EC; Kenyon, AJ; Michaels, EB, 1983
)
0.27
" C31G, a surface active anti-infective agent that is active in vitro against bacterial and viral STD pathogens, was evaluated in a 3-day, once-daily dosing clinical trial designed to assess multiple formulations for safety and acceptance."( Microbicides--evaluating multiple formulations of C31G.
Bax, R; Bowden, M; Douville, K; Higgins, J; McCormick, D; Rosenberg, M, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (16.13)18.7374
1990's9 (29.03)18.2507
2000's12 (38.71)29.6817
2010's5 (16.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.28 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index40.77 (26.88)
Search Engine Supply Index3.03 (0.95)

This Compound (26.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (35.48%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (64.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]